A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD)
Latest Information Update: 07 Jun 2024
At a glance
- Drugs Paricalcitol (Primary) ; Cisplatin; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic ductal carcinoma
- Focus Therapeutic Use
- Acronyms NABPLAGEMD
Most Recent Events
- 10 Apr 2024 Results presented at the 115th Annual Meeting of the American Association for Cancer Research
- 13 Dec 2023 Status changed from active, no longer recruiting to completed.
- 11 Apr 2023 Planned End Date changed from 31 Dec 2023 to 31 Jan 2024.